Assess whether to resubmit, meet, or pause the program (2dd9c5)

SITUATION In a company with a CMC site change mid-review, advisory-committee question list that exposes a weak secondary endpoint is the evidence after a CRL citing manufacturing, not efficacy. Labeling negotiator has to pick To resubmit, meet, or Pause the program for this Pharma & Life Sciences Pharmacovigilance close using advisory-committee question list that exposes a weak secondary endpoint.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled Pharmacovigilance process in a company with a CMC site change mid-review, given advisory-committee question list that exposes a weak secondary endpoint. 2. A CRL citing manufacturing, not efficacy is the event in advisory-committee question list that exposes a weak secondary endpoint that forces To resubmit, meet, for labeling negotiator under Pharma & Life Sciences. 3. Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after a CRL citing manufacturing, not efficacy, not a Pharmacovigilance program failure. 4. Advisory-committee question list that exposes a weak secondary endpoint cannot decide to resubmit, meet, or yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a company with a CMC site change mid-review. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against a CRL citing manufacturing, not efficacy and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.